Pathologic Complete Response Rates After Neoadjuvant Pertuzumab and Trastuzumab with Chemotherapy in Early Stage HER2-Positive Breast Cancer - Increasing Rates of Breast Conserving Surgery A Real-World Experience /
Purpose: The neoadjuvant use of pertuzumab and trastuzumab with chemotherapy improves the pathologic complete response (pCR) in early HER2+ breast cancer. The aim of this study was to determine the pCR rate obtained with dual HER2 blockade in routine clinical practice. The secondary and tertiary obj...
Elmentve itt :
| Szerzők: | |
|---|---|
| Dokumentumtípus: | Cikk |
| Megjelent: |
2021
|
| Sorozat: | PATHOLOGY AND ONCOLOGY RESEARCH
27 |
| Tárgyszavak: | |
| doi: | 10.3389/pore.2021.1609785 |
| mtmt: | 32049273 |
| Online Access: | http://publicatio.bibl.u-szeged.hu/35999 |